Tag: Hepatitis C | Page 4

A message from Laurie Edmiston

April 13, 2022 • By Laurie Edmiston

A message from Laurie Edmiston, executive director of CATIE: Dear friends and colleagues, It is with mixed emotions that I share with you my plans to retire this summer. As much as I love working at CATIE, there are many things I wish to do in life – maybe even during weekdays! In the nearly 19 years I’ve worked at CATIE, I have seen tremendous advances in science and in the community response to HIV and hepatitis C. When I joined the organization, our sole mandate was the provision of HIV treatment information. I’ve been honoured to lead our growth...

What I learned from teaching an HIV and hepatitis C testing course

February 2, 2022 • By Shelley Taylor

HIV treatments are a literal lifesaver and help people to live long and healthy lives, while also preventing transmission. There are also highly effective hepatitis C treatments that cure more than 95% of those living with the infection. But none of the advancements in hepatitis C and HIV treatment are being realized for the 13% of HIV-positive Canadians and 44% of Canadians with hepatitis C who don’t know their status. Testing is the first step towards connecting people to treatment, care and support, and no matter the result, it can also be the gateway to prevention services like harm reduction...

Hepatitis C reflex testing in Canada: from theory to practice

February 2, 2022 • By Romane Close

Hepatitis C testing in Canada can be complicated. Until recently, hepatitis C testing through provincial labs across the country was standard two-step testing. This approach uses two separate blood samples collected at two separate times. The first blood sample is for the screening test that looks for antibodies to the hepatitis C virus. This screening test determines if a person has ever been exposed to the virus. If this test result is positive, a second blood sample is taken to conduct the confirmatory test that looks for the presence of the hepatitis C virus in the blood. This test confirms...

Changing policies and addressing inequities: The health and wellbeing of people who use drugs

November 23, 2021 • By Rivka Kushner and Nikitah Habraken

The International Network on Health and Hepatitis in Substance Users (INHSU) expanded its mandate in 2020 beyond viral hepatitis to include the holistic health of people who use drugs, and from October 13 to 15, 2021, the organization hosted its first conference with this expanded mandate. Held virtually, this year’s conference brought together people with lived and living experience, healthcare and social service providers, researchers, advocates, policy-makers and community leaders to discuss promising practices, emerging trends, new research and what’s needed to support the health of people who use drugs around the world. An overarching theme of the conference related...

How Rwanda is eliminating hepatitis C and what Canada can learn from its successes

November 18, 2021 • By Dr. Jean Damascene Makuza, Dahn Jeong and Sofia Bartlett

Rwanda is a country situated in sub-Saharan, eastern Africa with a high population density: 499 people per square kilometre in 2018 and a population of 12.6 million people in 2019, an increase of 2.64% from 2018. Although it is among the poorest countries in the world and experienced a genocide against the Tutsi people in 1994, Rwanda has made immense progress in the fields of public health, achieving its Millennium Development Goals for population health, such as reduction of under-five mortality and maternal mortality.

Moving beyond risk-based testing: Checklist for supporting hepatitis C birth cohort screening

July 19, 2021 • By Dr. Sofia Bartlett, Stephanie Gin and Dr. Terri Buller-Taylor

British Columbia is the first province or territory in Canada to recommend one-time birth cohort screening for hepatitis C among people born from 1945 to 1965. This birth cohort has been identified as a key population that needs to be engaged into hepatitis C virus (HCV) care to reduce liver disease complications for several reasons: there are many undiagnosed cases of hepatitis C, they account for nearly 60% of positive hepatitis C results in B.C., and many people in this cohort have not received confirmatory HCV RNA testing.